Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations

24 Jul 2018

Abstract excerpt

// Christina Demuth 1, * , Anne Winther-Larsen 1, * , Anne Tranberg Madsen 1 , Peter Meldgaard 2 and Boe Sandahl Sorensen 1 1 Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark 2 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark * These authors have contributed equally to this work Correspondence to: Anne Winther-Larsen, email: Anne.Winther.Larsen@aarhus.rm.dk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30123427
DOI: 10.18632/oncotarget.25779

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutationsPMID 30123427Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyondSemantic proximity Read ↗

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patientsSemantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.Semantic proximity Read ↗

Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Semantic proximity Read ↗

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.